| 000 | 01592 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250512004811.0 | ||
| 264 | 0 | _c19890519 | |
| 008 | 198905s 0 0 eng d | ||
| 022 | _a0006-3223 | ||
| 024 | 7 |
_a10.1016/0006-3223(89)90197-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPickar, D | |
| 245 | 0 | 0 |
_aRepeated naloxone administration in schizophrenia: a phase II World Health Organization Study. _h[electronic resource] |
| 260 |
_bBiological psychiatry _cFeb 1989 |
||
| 300 |
_a440-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNaloxone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 |
_aReceptors, Opioid _xdrug effects |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 650 | 0 | 4 | _aSchizophrenic Psychology |
| 650 | 0 | 4 | _aWorld Health Organization |
| 700 | 1 | _aBunney, W E | |
| 700 | 1 | _aDouillet, P | |
| 700 | 1 | _aSethi, B B | |
| 700 | 1 | _aSharma, M | |
| 700 | 1 | _aVartanian, M E | |
| 700 | 1 | _aLideman, R P | |
| 700 | 1 | _aNaber, D | |
| 700 | 1 | _aLeibl, K | |
| 700 | 1 | _aYamashita, I | |
| 773 | 0 |
_tBiological psychiatry _gvol. 25 _gno. 4 _gp. 440-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0006-3223(89)90197-2 _zAvailable from publisher's website |
| 999 |
_c2545164 _d2545164 |
||